11/01/2019 21:05:00

Bioblast Pharma Ltd. Announces Receipt of Nasdaq Notification Regarding Minimum Stockholders’ Equity Non-Compliance

Tel Aviv, Israel, Jan. 11, 2019 (GLOBE NEWSWIRE) -- Bioblast Pharma Ltd. (NasdaqCM: ORPN) (“Bioblast” or the “Company”), a clinical-stage, orphan disease-focused biotechnology company, announced today that it received a written notification from the Listing Qualifications Department of The Nasdaq Capital Market (“Nasdaq”) notifying the Company that Nasdaq has determined that Bioblast’s stockholders’ equity does not comply with the minimum $2,500,000 stockholders’ equity requirement for continued listing on The Nasdaq Capital Market, as set forth in Nasdaq Listing Rule 5550(b)(1).

The Nasdaq notification does not affect the listing of the Company’s ordinary shares at this time.

The notification provides the company has until February 22, 2019, or 45 calendar days from the date of the notification, to submit to Nasdaq a plan to regain compliance with Nasdaq Listing Rule 5550(b)(1). The Company currently anticipates timely submitting such a plan to Nasdaq. If the plan is accepted, Nasdaq may grant an extension of up to 180 calendar days from the date of the notification for the Company to provide evidence of compliance. If the plan is not accepted or the Company is not granted an extension, Nasdaq staff could provide notice that the Company’s ordinary shares will become subject to delisting. In such event the Company may appeal the decision to reject its proposed compliance plan or any delisting determination to a Nasdaq Hearings Panel.

On November 19, 2018, the Company announced the entry into a definitive agreement to acquire Enlivex Therapeutics Ltd. (the “Transaction”).  The closing of the Transaction is expected to take place during the first quarter of 2019, and, upon closing, the Company expects to regain compliance with the minimum $2,500,000 stockholders’ equity requirement for continued listing on the Nasdaq Capital Market, subject to Nasdaq’s approval of the Company’s new listing application required in connection with the Transaction. On December 27, 2018, the shareholders of the Company approved requisite resolutions required to consummate the Transaction.

About Bioblast

Bioblast (NasdaqCM: ORPN) is a clinical-stage biotechnology company committed to developing clinically meaningful therapies for patients with rare and ultra-rare genetic diseases. For more information, please visit our website: www.bioblastpharma.com, the content of which is not incorporated herein by reference.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. For example, the Company is using forward-looking statements when it discusses submission of a plan to regain compliance with Nasdaq, that such plan will be accepted, the Company’s plan to close the Transaction and timing thereof, as well as that the Company is expected to regain compliance with Nasdaq listing rules upon closing of the Transaction. Because such statements deal with future events and are based on Bioblast’s current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of Bioblast could differ materially from those described in or implied by the statements in this press release, including those discussed under the heading “Risk Factors” in Bioblast’s Annual Report on Form 20-F filed with the Securities and Exchange Commission (“SEC”) on April 24, 2018 and Exhibit 99.2 to Bioblast’s Report on Form 6-K furnished to the SEC on December 6, 2018, and in any subsequent filings with the SEC. Except as otherwise required by law, Bioblast disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date hereof, whether as a result of new information, future events or circumstances or otherwise.

Contacts:

Bioblast Pharma, Ltd.

Dr. Dalia Megiddo, Interim CEO

dalia@bioblast-pharma.com

logo.png

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
18 Jan
I:SP500
  Hejsa    Jeg har igen vedlagt vores langsigtede konjunkturmodel med de ledende indikatorer i USA, ..
39
17 Jan
PNDORA
Jeg vil bare henlede opmærksomheden paa Lars Christensens artikel omkring "Short Selling", direkte h..
37
18 Jan
PNDORA
En stor tak til alle jer, der har givet mig en like (ialt 32). Det er dejligt at vide, at vi er mang..
20
19 Jan
I:NDX
Har lige opdaget at man kan trykke på en knap og sende en like. Men hvad skal man bruge det til? Alt..
18
19 Jan
 
Jeg deltog i går i en spørgeseance med CEO for Euronav Paddy Rodgers. Euronav er et pure play på råo..
18
16 Jan
VWS
Din indsigt i verdensfirmaet Vestas er forbløffende!
14
22 Jan
DANSKE
Det kan jo aldrig falde tilbage på en bank eller dens aktionærer at der er en flok institionelle inv..
13
22 Jan
GOMX
Update fra SASg i morges: 29 customers signed with expected annualised revenues of $10 - $12M from 1..
13
18 Jan
ROV
Ja, og de to ovenstående kommentarer er i den grad med til at forringe og forsimple debatniveauet he..
13
17 Jan
PNDORA
Udfordringen er, at der hele tiden sker en bekræftigelse af at Pandoras fald er faldende uden nogle ..
13

HSBC Bank Plc : Form 8.5 (EPT/RI) - Lonmin PLC

22/02/2018 10:54:53
FORM 8.5 EPT/RI) PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY Rule 8.5 of the Takeover Code (the "Code") 1.         KEY INFORMATION (a) Name of exempt principal trader: HSBC BANK PLC (b) Name of offeror/offeree i..

Rathbone Brothers Plc : Preliminary announcement of 2017 results

22/02/2018 07:00:19
Funds under management up 14.3% to £39.1 billionThis is a preliminary statement of annual results published in accordance with FCA Listing Rule 9.7A. It covers the year ended 31 December 2017. Mark Nicholls, Chairman of Rathbone Brothers Plc, said: "UK and global investment markets performed well in 2017, with some indices reaching record levels towards the end of the year. This outcome has b..

Elliott Capital Advisors, L.P : Form 8.3 - GKN Plc

21/02/2018 15:25:10
FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the "Code") 1.         KEY INFORMATION (a) Full name of discloser: Elliott Capital Advisors, L.P. (for itself and related general partners ..

Most read news

  • 24 hours
  • 48 hours
  • 1 week
1
LoRa Alliance Passes 100 LoRaWAN™ Network Operator Milestone with Coverage in 100 Countries
2
General Cannabis Continues Expansion with Latest Office Opening in Los Angeles and Renovation of 15,000 Square Foot Denver Headquarters
3
Distilled Identity and Emerge Announce Technology Partnership to Solve Global Identity Crisis for Refugees
4
Bloomington-Normal Association of Realtors® Successfully Goes Live with Midwest Real Estate Data
5
Update on Parys Mountain Optimisation Study

Buy and sell signals

  • Trend
  • Moneymachine

Copyright Berlingske Media 2019  Cookie- and Privacy policy  |  Cookies  |   General terms of trade  |   Terms of use and IP rights
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
23 January 2019 01:50:59
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: ReleaseBuild_20190121.1 - EUROWEB6 - 2019-01-23 02:50:59 - 2019-01-23 01:50:59 - 1000 - Website: OKAY